Clinical Trial: Orelabrutinib Plus ICP 248 vs Orelabrutinib for Relapsed/Refractory Marginal Zone Lymphoma

U.S., Oct. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07896590) titled 'Orelabrutinib Plus ICP 248 vs Orelabrutinib for Relapsed/Refractory Marginal Zone Lymphoma' on Oct. 19.

Brief Summary: To evaluate the efficacy of olubrutinib combined with ICP-248 compared with the olubrutinib in the treatment of r/r MZL

Study Start Date: Oct., 2026

Study Type: INTERVENTIONAL

Condition: Relapsed/Refractory Marginal Zone Lymphoma (MZL)

Intervention: DRUG: Orelabrutinib

Participants receive orelabrutinib 150 mg oral once daily continuous dosing; each cycle is 28 days.

DRUG: ICP-248

Eligible patients will receive ICP-248 orally as per the protocol

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Beijing Inno...